← Eichor
Study identifier: NCT03016806 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Umbilical Cord Blood Transplantation From Unrelated Donors

Condition: Acute Leukemia · Immune Deficiency Disorder · Congenital Hematological Disorder  ·  Sponsor: University of Rochester

PhaseN/A
Planned participants30
Who can joinAll sexes, 2 Months to 75 Years
Healthy volunteersNo

About this study

This study is being done to determine how long it takes for the engraftment (recovery of blood cell counts) of umbilical cord stem cells and also how often engraftment of umbilical cord stem cells transplanted from an unrelated donor fails. Another purpose will be to document the rate of disease-free survival and the rate of relapse (a return of your disease or syndrome) as well as the incidence and severity of graft versus host disease (GvHD) following cord blood stem cell transplantation. GvHD is a complication of stem cell transplants in which white blood cells from the transplanted tissue (graft) attack the transplant recipient's body (host).

This description comes directly from the study's public registry record.

Talk to the study team

Omar Aljitawi, MD  ·  585-275-4099  ·  omar_aljitawi@urmc.rochester.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Wilmot Cancer InstituteRochester, New York, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT03016806